Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia

Introduction: Naftopidil, approved initially in Japan, is an α1d-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is different from tamsulosin hydrochloride and silodosin, in that it has a higher affinity for...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mahavir Singh Griwan, Y. R. Karthikeyan, Mandeep Kumar, Bikram Jit Singh, Santosh Kumar Singh
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wolters Kluwer Medknow Publications 2014-01-01
coleção:	Urology Annals
Assuntos:	Benign prostatic hyperplasia LUTS naftopidil tamsulosin
Acesso em linha:	http://www.urologyannals.com/article.asp?issn=0974-7796;year=2014;volume=6;issue=3;spage=181;epage=186;aulast=Griwan
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!